Work

Dual A2A/A2B Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth In Vivo

Year: 2024

Type: article

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.mct-23-0843

Authors: Kai Schiemann, Natalya Belousova, Armine Matevossian, Kalyan C. Nallaparaju, Giorgio Kradjian, Meghana Pandya, Zhouxiang Chen, Esengul Aral, Eva-Maria Krauel, Elissaveta Petrova, Carsten Boesler, Thomas Kitzing, Marc Lecomte, Christian Wagner, Anne Laure Blayo, Stephan Schann, Bayard Huck, Jacques Moisan, Rinat Zaynagetdinov

Institutions: Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), EMD Serono, Inc. (United States), Domain Therapeutics (France)

Language: English

Topic: Adenosine and Purinergic Signaling

Subfield: Physiology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4401715188

FWCI: 6.506

Cites: 49

Cited by: 26

Related to: 10